Clinical Trial: GenSci143 in Participants With Advanced Solid Tumors

U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07252414) titled 'GenSci143 in Participants With Advanced Solid Tumors' on Nov. 14.

Brief Summary: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors

Study Start Date: Dec. 20

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: DRUG: GenSci143 for injection

GenSci143 for injection, administered Q3W, with a dosage ranging from 0.5mg/kg to 4.5mg/kg.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Disclaimer: Curated by HT Syndication....